Zealand CEO has full confidence in Sanofi
Zealand Pharma’s CEO Britt Meelby Jensen does not see a recent delay as a sign that partner Sanofi will fail to win approval of a new combo treatment for diabetes. She has full confidence in both the commercial potential of the drug and Sanofi’s organization, but admits she would have preferred to be in control of the matter.
BY STEFAN SINGH KAILAY
Recent news that Sanofi and Zealand Pharma would see a three month delay on a decision concerning possible US approval of the companies’ next big diabetes hope, iGlarLixi, disappointed the stock market and sent the Danish biotech company’s share price tumbling by about 7 percent in the beginning of the week. But CEO Britt Meelby Jensen maintains that the delay is nothing more than a delay.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand and Sanofi’s blockbuster dreams hit a snag
For abonnenter
Pace sets Zealand apart from larger rivals
For abonnenter
